CoronaryAtlas logo
CoronaryAtlas
Versican
Pathway / Fibrous-cap degradation & rupture

Versican

VCANprotein

Versican remodeling in the fibrous cap reduces structural integrity and promotes cap degradation.

Pathway placement
Cascade stepFibrous-cap degradation & rupture
Confidencemedium
RationaleECM proteoglycan; versican loss/cleavage weakens fibrous cap and increases rupture risk.
Also acts inEndothelial activation/erosion, Vascular inflammation
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000038427

Type I vs non-Type I discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
43
C — non-Type-I
56
A — assay feasibility
68
E — evidence strength
23
T1DI (composite)
7
Specificity differential (R−C)-12.3
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(3)